Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout

BACKGROUND: Dotinurad is a novel selective urate reabsorption inhibitor (SURI) which reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1). This study was intended to verify the efficacy and safety of dotinurad following treatment for 34 or 58 weeks in hyperuricemic pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosoya, Tatsuo, Fushimi, Masahiko, Okui, Daisuke, Sasaki, Tomomitsu, Ohashi, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066281/
https://www.ncbi.nlm.nih.gov/pubmed/31875931
http://dx.doi.org/10.1007/s10157-019-01831-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066281/
https://www.ncbi.nlm.nih.gov/pubmed/31875931
http://dx.doi.org/10.1007/s10157-019-01831-5

Ejemplares similares